| Patent Publications | |||||||||
Just recently, several AZAD patents have been published with many more to follow in the future!
|
2018 August - Announcement of exclusive agreement of RGP with AZAD | ||||||||
| AZAD Pharmaceutical Ingredients (Schaffhausen/Switzerland) is pleased to announce that RG Pharmaceutica (Pvt) Ltd is our exclusive agent for iron sucrose in Pakistan. AZAD Pharmaceutical Ingredients is providing Iron Sucrose API manufactured by Cilag along with the technical support to RG Pharmaceutica for manufacturing & commercialization of Iron sucrose under the brand name of Onefer®. | |||||||||
| 2018 July - Riociguat Project | |||||||||
The first scientific article reflecting some results of research performed in the lab, within the framework of "Riociguat" project, has been published recently in “Der Pharma Chemica” journal. Journal Article |
|||||||||
| 2018 June - Scientific Article published in ZHAW Impact University Magazine | |||||||||
A short article about the collaboration of our API R&D with the research group of Dr. Christian Frech (ZHAW Wädenswil) has been published in the most recent issue of the ZHAW Impact University Magazine.
ZHAW Impact 41/18: |
|||||||||
| 2018 June - 1st International Scientific Conference | |||||||||
AZAD proudly presents the 1st International Scientific Conference “Current State of Pharmacy and Prospects of its Development”, November 01-03, 2018, Yerevan. The conference will be take place at the Yerevan State University, Institute of Pharmacy. AZAD is part of the organization committee and will also be part of the Scientific and Honorary Committees. |
|||||||||
| 2018 January - New CTI Project 27582.1 PFLS-LS | |||||||||
| The CTI approval committee (Commission for Technology and Innovation) has reviewed the third application of the research group of PD Dr. Christian Frech (ZHAW) and AZAD and concluded that also this proposed research project qualifies for CTI grant funding.
The funding for CTI Project 27582.1 PFLS-LS is granted the "Development of a patent non-infringing synthesis of a recently approved API for cancer treatment". The funding is granted for a maximum period of 32 months starting in spring 2018 which elongates the successful collaboration of the research group of PD Dr. Christian Frech and AZAD until the end of 2020. |
|||||||||
| 2017 – August – Computer science apprentices at AZAD | |||||||||
| AZAD Pharmaceutical Ingredients AG now trains computer science apprentices who'll start their training on 2nd of August and will end in August 2021. |
|||||||||
| 2017 - March - AZAD privileges from Armenian Government | |||||||||
Please see the following link to the YouTube video: Armenian Government provides privileges to AZAD Pharmaceutical Ingredients LLC |
|||||||||
| 2016 - November - Armenia gateway to major markets | |||||||||
Please see the following link to the YouTube video: |
|||||||||
| 2016 - October - CPhI Barcelona | |||||||||
Thank you very much for visiting us at our booth at CPHI. See you next year in Frankfurt!
|
|||||||||
| 2016 - July - CPhI Barcelona | |||||||||
AZAD Pharma AG and AZAD Pharmaceutical Ingredients AG will attend this year's CPhI in Barcelona in October 2016. We look forward to seeing you there! |
|||||||||
| 2016 - March - second CTI Project | |||||||||
After the successful finalization of the first CTI project the CTI approval committee (Commission for Technology and Innovation) has reviewed a second application and concluded that also this proposed research project qualifies for CTI grant funding for a research and development of new, non-IP protected synthetic route for an API for major depressive disorder treatment. |
|||||||||
| 2015 - December - DCAT | |||||||||
| As a DCAT member, AZAD will be attending DCAT in New York City, USA on March 14-17, 2016 | |||||||||
| 2015 - April - CTI Project | |||||||||
AZAD and the Zurich University of Applied Sciences (Zürcher Hochschule für Angewandte Wissenschaften, ZHAW), Wädenswil receive commitment for a Commission for Technology and Innovation (CTI) project. |
|||||||||
| 2015 - February - CPhI Madrid | |||||||||
| AZAD Pharma AG and AZAD Pharmaceutical Ingredients AG will attend this year's CPhI in Madrid from 13-15 October 2015. We look forward to seeing you there! | |||||||||
| 2014 - January - Research using Iron Sucrose AZAD | |||||||||
| To answer the EMEA Reflection paper “non-clinical studies for generic nanoparticle medicinal product applications” AZAD commission in vitro and in vivo non-clinical studies to compare the biodistribution and cellular handling of iron sucrose Azad with the original product Venofer®, whereby their properties were found to be essentially similar. These studies have recently been published in peer-reviewed journals, see attachments. | |||||||||
 |
|
|
|||||||
Journal of Pharmacological and Toxicological Methods Biodistribution and predictive hepatic gene expression of intravenous iron sucrose |
Therapeutics for States of Deficiency Physicochemical and toxicological characterization |
Pharmaceutical Development and Technology Bioavailability and stability of intravenous iron sucrose originator |
|||||||
| 2013 - October - AZAD successfully completes Phase III trial of generic Brinzolamide ophthalmic suspension | |||||||||
AZAD Pharma sponsored this phase III, multicentre, randomized, investigator-masked, cross-over, comparative efficacy study of its generic Brinzolamide 10mg/ml ophthalmic suspension and Brinzolamide 10mg/ml ophthalmic suspension (Azopt®, Alcon) in open-angle glaucoma and ocular hypertension patients. |
|||||||||
